HEOR, RWE and Market Access
Welcome to the HEOR, RWE and Market Access knowledge hub.
As healthcare moves towards decision-making driven by evidence and value, there is increased demand for health economics outcomes research (HEOR), real world data (RWD), real world evidence (RWE) and market access capabilities. Scientist.com streamlines the sourcing of these services by increasing your ability to utilize the best solution providers, reducing time to contract and enabling quicker time to insight, all of which improve patient and market access.
Popular Services Click here for a full list
HEOR, RWE and Market Access Features
At Scientist.com, you can now access hundreds of suppliers of HEOR, RWE/RWD and Market Access services, with this number increasing monthly. By using our category-specific RFI, biopharma buyers can more easily and confidently identify suppliers with the desired capabilities, subject matter expertise or data access to meet specific needs.
Scientist.com has also expanded the number of Real World Data providers as well as firms with value communication expertise, thereby complementing our established areas of RWE, Health Economics and Market Access.
Resources from HealthEconomics.com – a Scientist.com company:
In 2020, Scientist.com completed the acquisition of our longtime partner HealthEconomics.com to support the growing demand for HEOR, RWE and Market Access services. They are the world’s largest digital CONNECTED COMMUNITY™ that provides a single global link to the health economic and outcomes research (HEOR), real-world evidence (RWE), and Market Access (MA) stakeholder communities.
Resources available from HealthEconomics.com include:
- tHEORetically Speaking Blog – the official blog of HealthEconomics.com
- Industry White Papers
- Syndicated Reports
- Conferences
- Webinars
- Industry News (RSS)
HealthEconomics.com News Feed
tHEORetically Speaking -Is the US Quietly Building an HTA System?Explore how the U.S. is adopting HTA-like processes in its healthcare system. With rising costs and new legislative measures, stakeholders face a fragmented but evolving landscape of value assessment and drug pricing negotiations. The post Is the US Quietly Building an HTA System? appeared first on HealthEconomics.com. Alkermes Advances Narcolepsy Drug Following Positive Study ResultsDiscover how Alkermes' drug alixorexton shows promise in treating narcolepsy type 1 by significantly improving wakefulness without serious side effects. As Alkermes prepares for global Phase 3 trials, the competitive orexin drug market anticipates substantial sales, amid investor caution. The post Alkermes Advances Narcolepsy Drug Following Positive Study Results appeared first on HealthEconomics.com. Bristol Myers and Pfizer Introduce Discounted Eliquis ProgramBristol Myers Squibb and Pfizer are offering a 40% discount on Eliquis for uninsured patients, bypassing traditional drug distribution channels. The post Bristol Myers and Pfizer Introduce Discounted Eliquis Program appeared first on HealthEconomics.com. |
Media and News Center
This installment was written by xCures, whose mission is to improve cancer outcomes using A.I. and predictive modeling. With the explosion of AI...
On September 21, Scientist.com and speakers from PRECISIONheor, PRMA Consulting and OpenHealth participated in the second episode of the Cutting...
Scientist.com, the parent company of HealthEconomics.Com, recently announced the newly rebranded Value, Evidence and Access Marketplace – an online...